{"schema_version":"secwatch.filing_event.v1","accession":"0001618835-23-000011","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.849901+00:00","generated_at":"2026-06-19T02:43:15.050386+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Evofem Biosciences raises ~$739k net via sale of convertible notes and warrants","bullets":["Aggregate principal $1.38M; net proceeds ~$739k after expenses.","Notes bear 8% interest, mature in 3 years, convertible at $0.02/share.","Warrants exercisable at $0.02/share, expire in 5 years.","Beneficial ownership limitation of 4.99% applies to conversion/exercise.","Registration rights agreement filed for resale of underlying shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001618835-23-000011","json":"https://secwatch.observer/filing/0001618835-23-000011.json","markdown":"https://secwatch.observer/filing/0001618835-23-000011.md","text":"https://secwatch.observer/filing/0001618835-23-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000161883523000011/0001618835-23-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000161883523000011/evfm-20230217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:43:15.050386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41dea62b1f202ffec066809d68f809c48e464a5e","claim":"Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at aggregate original principal amount of $1,384,615.39 (effective 2023-02-17).","evidence_excerpt":"On February 17, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company” ), entered into a securities purchase agreement (“ SPA” ), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $1,384,615.39 (the “ Notes” ) and warrants (“ Warrants” ) to purchase an aggregate 69,230,769 shares of common stock, par value $0.0001 per share (the “ Common Stock ”) (collectively, the “ Offering” ). The Offering closed on February 17, 2023 (the “ Closing Date” ) and as a result, the Company issued an aggregate $1,384,615.39 in the aggregate principal amount of Notes and Warrants to purchase 69,230,769 shares of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000161883523000011/0001618835-23-000011-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"aggregate original principal amount of $1,384,615.39"},{"label":"Effective","value":"2023-02-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}